340 related articles for article (PubMed ID: 33233631)
1. Purinergic Signaling in Pancreas-From Physiology to Therapeutic Strategies in Pancreatic Cancer.
Novak I; Yu H; Magni L; Deshar G
Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33233631
[TBL] [Abstract][Full Text] [Related]
2. The metabolic milieu in melanoma: Role of immune suppression by CD73/adenosine.
Passarelli A; Tucci M; Mannavola F; Felici C; Silvestris F
Tumour Biol; 2019 Apr; 42(4):1010428319837138. PubMed ID: 30957676
[TBL] [Abstract][Full Text] [Related]
3. Global targetome analysis reveals critical role of miR-29a in pancreatic stellate cell mediated regulation of PDAC tumor microenvironment.
Dey S; Liu S; Factora TD; Taleb S; Riverahernandez P; Udari L; Zhong X; Wan J; Kota J
BMC Cancer; 2020 Jul; 20(1):651. PubMed ID: 32660466
[TBL] [Abstract][Full Text] [Related]
4. CD73 induces gemcitabine resistance in pancreatic ductal adenocarcinoma: A promising target with non-canonical mechanisms.
Yu X; Liu W; Wang Z; Wang H; Liu J; Huang C; Zhao T; Wang X; Gao S; Ma Y; Wu L; Li X; Yang S; Hao J
Cancer Lett; 2021 Oct; 519():289-303. PubMed ID: 34302921
[TBL] [Abstract][Full Text] [Related]
5. Regulation of immune responses through CD39 and CD73 in cancer: Novel checkpoints.
Baghbani E; Noorolyai S; Shanehbandi D; Mokhtarzadeh A; Aghebati-Maleki L; Shahgoli VK; Brunetti O; Rahmani S; Shadbad MA; Baghbanzadeh A; Silvestris N; Baradaran B
Life Sci; 2021 Oct; 282():119826. PubMed ID: 34265363
[TBL] [Abstract][Full Text] [Related]
6. Pancreatic stellate cell: Pandora's box for pancreatic disease biology.
Bynigeri RR; Jakkampudi A; Jangala R; Subramanyam C; Sasikala M; Rao GV; Reddy DN; Talukdar R
World J Gastroenterol; 2017 Jan; 23(3):382-405. PubMed ID: 28210075
[TBL] [Abstract][Full Text] [Related]
7. Targeting of the P2X7 receptor in pancreatic cancer and stellate cells.
Giannuzzo A; Saccomano M; Napp J; Ellegaard M; Alves F; Novak I
Int J Cancer; 2016 Dec; 139(11):2540-52. PubMed ID: 27513892
[TBL] [Abstract][Full Text] [Related]
8. Targeting the tumor microenvironment for pancreatic ductal adenocarcinoma therapy.
Zhang YF; Jiang SH; Hu LP; Huang PQ; Wang X; Li J; Zhang XL; Nie HZ; Zhang ZG
Chin Clin Oncol; 2019 Apr; 8(2):18. PubMed ID: 31070038
[TBL] [Abstract][Full Text] [Related]
9. Neutrophil in the Pancreatic Tumor Microenvironment.
Jin L; Kim HS; Shi J
Biomolecules; 2021 Aug; 11(8):. PubMed ID: 34439836
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of the expression and function of the P2X7 receptor and ART1 in human regulatory T-cell subsets.
Cortés-Garcia JD; López-López C; Cortez-Espinosa N; García-Hernández MH; Guzmán-Flores JM; Layseca-Espinosa E; Portales-Cervantes L; Portales-Pérez DP
Immunobiology; 2016 Jan; 221(1):84-93. PubMed ID: 26307000
[TBL] [Abstract][Full Text] [Related]
11. The P2X7 Receptor Stimulates IL-6 Release from Pancreatic Stellate Cells and Tocilizumab Prevents Activation of STAT3 in Pancreatic Cancer Cells.
Magni L; Bouazzi R; Heredero Olmedilla H; Petersen PSS; Tozzi M; Novak I
Cells; 2021 Jul; 10(8):. PubMed ID: 34440697
[TBL] [Abstract][Full Text] [Related]
12. Galectin-3 Mediates Tumor Cell-Stroma Interactions by Activating Pancreatic Stellate Cells to Produce Cytokines via Integrin Signaling.
Zhao W; Ajani JA; Sushovan G; Ochi N; Hwang R; Hafley M; Johnson RL; Bresalier RS; Logsdon CD; Zhang Z; Song S
Gastroenterology; 2018 Apr; 154(5):1524-1537.e6. PubMed ID: 29274868
[TBL] [Abstract][Full Text] [Related]
13. Current Status of Immunotherapies for Treating Pancreatic Cancer.
Wu AA; Jaffee E; Lee V
Curr Oncol Rep; 2019 May; 21(7):60. PubMed ID: 31101991
[TBL] [Abstract][Full Text] [Related]
14. Immune Checkpoint Inhibition for Pancreatic Ductal Adenocarcinoma: Current Limitations and Future Options.
Kabacaoglu D; Ciecielski KJ; Ruess DA; Algül H
Front Immunol; 2018; 9():1878. PubMed ID: 30158932
[TBL] [Abstract][Full Text] [Related]
15. Local and systemic immunosuppression in pancreatic cancer: Targeting the stalwarts in tumor's arsenal.
Mundry CS; Eberle KC; Singh PK; Hollingsworth MA; Mehla K
Biochim Biophys Acta Rev Cancer; 2020 Aug; 1874(1):188387. PubMed ID: 32579889
[TBL] [Abstract][Full Text] [Related]
16. The ectonucleotidases CD39 and CD73: Novel checkpoint inhibitor targets.
Allard B; Longhi MS; Robson SC; Stagg J
Immunol Rev; 2017 Mar; 276(1):121-144. PubMed ID: 28258700
[TBL] [Abstract][Full Text] [Related]
17. Disruption of Super-Enhancers in Activated Pancreatic Stellate Cells Facilitates Chemotherapy and Immunotherapy in Pancreatic Cancer.
Wang Y; Chen K; Liu G; Du C; Cheng Z; Wei D; Li F; Li C; Yang Y; Zhao Y; Nie G
Adv Sci (Weinh); 2024 Apr; 11(16):e2308637. PubMed ID: 38417121
[TBL] [Abstract][Full Text] [Related]
18. ATP and adenosine: Role in the immunopathogenesis of rheumatoid arthritis.
da Silva JLG; Passos DF; Bernardes VM; Leal DBR
Immunol Lett; 2019 Oct; 214():55-64. PubMed ID: 31479688
[TBL] [Abstract][Full Text] [Related]
19. Targeting Purinergic Receptor P2Y2 Prevents the Growth of Pancreatic Ductal Adenocarcinoma by Inhibiting Cancer Cell Glycolysis.
Hu LP; Zhang XX; Jiang SH; Tao LY; Li Q; Zhu LL; Yang MW; Huo YM; Jiang YS; Tian GA; Cao XY; Zhang YL; Yang Q; Yang XM; Wang YH; Li J; Xiao GG; Sun YW; Zhang ZG
Clin Cancer Res; 2019 Feb; 25(4):1318-1330. PubMed ID: 30420446
[TBL] [Abstract][Full Text] [Related]
20. The distinct role of CD73 in the progression of pancreatic cancer.
Zhou L; Jia S; Chen Y; Wang W; Wu Z; Yu W; Zhang M; Ding G; Cao L
J Mol Med (Berl); 2019 Jun; 97(6):803-815. PubMed ID: 30927045
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
